Click here to get full coverage on IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA - GlobeNewswire

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA  GlobeNewswire

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA - GlobeNewswire

Click here to get full coverage on Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?  Yahoo Finance

Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Click here to get full coverage on Immunovant, Inc. $IMVT Shares Bought by Woodline Partners LP - MarketBeat

Immunovant, Inc. $IMVT Shares Bought by Woodline Partners LP  MarketBeat

Immunovant, Inc. $IMVT Shares Bought by Woodline Partners LP - MarketBeat

Click here to get full coverage on IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT - Business Wire

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT  Business Wire

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT - Business Wire

Click here to get full coverage on Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage - FirstWord Pharma

Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage  FirstWord Pharma

Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage - FirstWord Pharma

Click here to get full coverage on Notable Thursday Option Activity: IMVT, RBLX, MEG - Nasdaq

Notable Thursday Option Activity: IMVT, RBLX, MEG  Nasdaq

Notable Thursday Option Activity: IMVT, RBLX, MEG - Nasdaq

Click here to get full coverage on Immunovant (IMVT) Valuation in Focus Following New Batoclimab Clinical Data Announcement - simplywall.st

Immunovant (IMVT) Valuation in Focus Following New Batoclimab Clinical Data Announcement  simplywall.st

Immunovant (IMVT) Valuation in Focus Following New Batoclimab Clinical Data Announcement - simplywall.st

Click here to get full coverage on $IMVT stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

$IMVT stock is up 8% today. Here's what we see in our data.  Quiver Quantitative

$IMVT stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Immunovant Launches New Clinical Trials, Reports $599M Cash Position | IMVT Stock News - Stock Titan

Immunovant Launches New Clinical Trials, Reports $599M Cash Position | IMVT Stock News  Stock Titan

Immunovant Launches New Clinical Trials, Reports $599M Cash Position | IMVT Stock News - Stock Titan

Click here to get full coverage on Immunovant will not seek approval for MG therapy, despite hitting endpoints - Clinical Trials Arena

Immunovant will not seek approval for MG therapy, despite hitting endpoints  Clinical Trials Arena

Immunovant will not seek approval for MG therapy, despite hitting endpoints - Clinical Trials Arena

Click here to get full coverage on LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN

LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT  MSN

LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT - MSN

Click here to get full coverage on IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results - Yahoo Finance

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results  Yahoo Finance

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results - Yahoo Finance

Click here to get full coverage on Adage Capital Partners GP L.L.C. Has $362,000 Position in Immunovant, Inc. $IMVT - MarketBeat

Adage Capital Partners GP L.L.C. Has $362,000 Position in Immunovant, Inc. $IMVT  MarketBeat

Adage Capital Partners GP L.L.C. Has $362,000 Position in Immunovant, Inc. $IMVT - MarketBeat

Click here to get full coverage on Can Immunovant's (IMVT) New Data on Batoclimab Reveal a Path to Durable Innovation? - simplywall.st

Can Immunovant's (IMVT) New Data on Batoclimab Reveal a Path to Durable Innovation?  simplywall.st

Can Immunovant's (IMVT) New Data on Batoclimab Reveal a Path to Durable Innovation? - simplywall.st

Click here to get full coverage on Cubist Systematic Strategies LLC Raises Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat

Cubist Systematic Strategies LLC Raises Stock Holdings in Immunovant, Inc. $IMVT  MarketBeat

Cubist Systematic Strategies LLC Raises Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat

Click here to get full coverage on Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?  Yahoo Finance

Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Click here to get full coverage on Immunovant, Inc. $IMVT is Two Seas Capital LP's 10th Largest Position - MarketBeat

Immunovant, Inc. $IMVT is Two Seas Capital LP's 10th Largest Position  MarketBeat

Immunovant, Inc. $IMVT is Two Seas Capital LP's 10th Largest Position - MarketBeat

Click here to get full coverage on Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High? - Yahoo Finance

Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?  Yahoo Finance

Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High? - Yahoo Finance

Click here to get full coverage on Trial of Sjögren's treatment IMVT-1402 slated to launch in summer - Sjogren's Disease News

Trial of Sjögren's treatment IMVT-1402 slated to launch in summer  Sjogren's Disease News

Trial of Sjögren's treatment IMVT-1402 slated to launch in summer - Sjogren's Disease News

Click here to get full coverage on Immunovant, Inc. Reports Progress on IMVT-1402 Development and Financial Results for Fiscal Q3 2024 - Nasdaq

Immunovant, Inc. Reports Progress on IMVT-1402 Development and Financial Results for Fiscal Q3 2024  Nasdaq

Immunovant, Inc. Reports Progress on IMVT-1402 Development and Financial Results for Fiscal Q3 2024 - Nasdaq

Click here to get full coverage on IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm  Business Wire

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

Click here to get full coverage on Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack (NASDAQ:ROIV) - Seeking Alpha

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack (NASDAQ:ROIV)  Seeking Alpha

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack (NASDAQ:ROIV) - Seeking Alpha

Click here to get full coverage on Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role - Stock Titan

Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role  Stock Titan

Immunovant's Major Growth Push: Drug Pipeline Hits 6 Indications as Roivant Executive Takes CEO Role - Stock Titan

Click here to get full coverage on Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025 - Yahoo Finance

Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025  Yahoo Finance

Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025 - Yahoo Finance

Click here to get full coverage on 80% of Patients Maintain Normal Thyroid Function: Immunovant's Breakthrough in Graves' Disease Treatment Study - Stock Titan

80% of Patients Maintain Normal Thyroid Function: Immunovant's Breakthrough in Graves' Disease Treatment Study  Stock Titan

80% of Patients Maintain Normal Thyroid Function: Immunovant's Breakthrough in Graves' Disease Treatment Study - Stock Titan

Click here to get full coverage on We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely - simplywall.st

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely  simplywall.st

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely - simplywall.st

Click here to get full coverage on Granahan Investment Management LLC Increases Holdings in Immunovant, Inc. $IMVT - MarketBeat

Granahan Investment Management LLC Increases Holdings in Immunovant, Inc. $IMVT  MarketBeat

Granahan Investment Management LLC Increases Holdings in Immunovant, Inc. $IMVT - MarketBeat

Click here to get full coverage on IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success - Yahoo Finance

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success  Yahoo Finance

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success - Yahoo Finance

Click here to get full coverage on Immunovant won't seek approval for autoimmune drug despite phase 3 win - Fierce Biotech

Immunovant won't seek approval for autoimmune drug despite phase 3 win  Fierce Biotech

Immunovant won't seek approval for autoimmune drug despite phase 3 win - Fierce Biotech

Click here to get full coverage on US Market Recap: How much upside does IMVT have - 2025 Historical Comparison & Consistent Profit Trading Strategies - خودرو بانک

US Market Recap: How much upside does IMVT have - 2025 Historical Comparison & Consistent Profit Trading Strategies  خودرو بانک

US Market Recap: How much upside does IMVT have - 2025 Historical Comparison & Consistent Profit Trading Strategies - خودرو بانک

Click here to get full coverage on Immunovant's Clinical Trials Show 74% Success in Myasthenia Gravis, Advancing 6 Disease Programs - Stock Titan

Immunovant's Clinical Trials Show 74% Success in Myasthenia Gravis, Advancing 6 Disease Programs  Stock Titan

Immunovant's Clinical Trials Show 74% Success in Myasthenia Gravis, Advancing 6 Disease Programs - Stock Titan

Click here to get full coverage on IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - PR Newswire

IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm  PR Newswire

IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - PR Newswire

Click here to get full coverage on Immunovant's (IMVT) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Immunovant's (IMVT) "Buy" Rating Reiterated at HC Wainwright  MarketBeat

Immunovant's (IMVT) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Click here to get full coverage on Immunovant, Inc. $IMVT Shares Purchased by Alpine Global Management LLC - MarketBeat

Immunovant, Inc. $IMVT Shares Purchased by Alpine Global Management LLC  MarketBeat

Immunovant, Inc. $IMVT Shares Purchased by Alpine Global Management LLC - MarketBeat

Click here to get full coverage on $IMVT stock is up 2% today. Here's what we see in our data. - Quiver Quantitative

$IMVT stock is up 2% today. Here's what we see in our data.  Quiver Quantitative

$IMVT stock is up 2% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Aug Movers: Is IMVT stock risky to hold now - Market Growth Report & Fast Moving Market Watchlists - خودرو بانک

Aug Movers: Is IMVT stock risky to hold now - Market Growth Report & Fast Moving Market Watchlists  خودرو بانک

Aug Movers: Is IMVT stock risky to hold now - Market Growth Report & Fast Moving Market Watchlists - خودرو بانک

Click here to get full coverage on Investor Mood: What’s the outlook for IMVT’s sector - July 2025 Final Week & Accurate Entry/Exit Alerts - خودرو بانک

Investor Mood: What’s the outlook for IMVT’s sector - July 2025 Final Week & Accurate Entry/Exit Alerts  خودرو بانک

Investor Mood: What’s the outlook for IMVT’s sector - July 2025 Final Week & Accurate Entry/Exit Alerts - خودرو بانک

Click here to get full coverage on DAFNA Capital Management LLC Boosts Holdings in Immunovant, Inc. $IMVT - MarketBeat

DAFNA Capital Management LLC Boosts Holdings in Immunovant, Inc. $IMVT  MarketBeat

DAFNA Capital Management LLC Boosts Holdings in Immunovant, Inc. $IMVT - MarketBeat

Click here to get full coverage on IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus - Zacks Investment Research

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus  Zacks Investment Research

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus - Zacks Investment Research

Click here to get full coverage on Immunovant claims study success for immune disease drug but holds off on submission - BioPharma Dive

Immunovant claims study success for immune disease drug but holds off on submission  BioPharma Dive

Immunovant claims study success for immune disease drug but holds off on submission - BioPharma Dive

Click here to get full coverage on Batoclimab eases disease severity; Immunovant backs IMVT-1402 - Myasthenia Gravis News

Batoclimab eases disease severity; Immunovant backs IMVT-1402  Myasthenia Gravis News

Batoclimab eases disease severity; Immunovant backs IMVT-1402 - Myasthenia Gravis News

Click here to get full coverage on Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nasdaq

Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner  Nasdaq

Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nasdaq

Click here to get full coverage on Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study (NASDAQ:IMVT) - Seeking Alpha

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study (NASDAQ:IMVT)  Seeking Alpha

Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study (NASDAQ:IMVT) - Seeking Alpha

Click here to get full coverage on Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus - Yahoo Finance

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus  Yahoo Finance

Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus - Yahoo Finance

Click here to get full coverage on Despite Phase III success in myasthenia gravis, Immunovant shifts to successor drug - FirstWord Pharma

Despite Phase III success in myasthenia gravis, Immunovant shifts to successor drug  FirstWord Pharma

Despite Phase III success in myasthenia gravis, Immunovant shifts to successor drug - FirstWord Pharma

Click here to get full coverage on Join the Immunovant (IMVT) Securities Lawsuit: 30% Stock Drop - Claim Depot

Join the Immunovant (IMVT) Securities Lawsuit: 30% Stock Drop  Claim Depot

Join the Immunovant (IMVT) Securities Lawsuit: 30% Stock Drop - Claim Depot

Click here to get full coverage on Insider Sale: Chief Technology Officer of $IMVT Sells 1,519 Shares - Quiver Quantitative

Insider Sale: Chief Technology Officer of $IMVT Sells 1,519 Shares  Quiver Quantitative

Insider Sale: Chief Technology Officer of $IMVT Sells 1,519 Shares - Quiver Quantitative

Click here to get full coverage on Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade) - Seeking Alpha

Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade)  Seeking Alpha

Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade) - Seeking Alpha

Click here to get full coverage on Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 - Yahoo Finance

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025  Yahoo Finance

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 - Yahoo Finance

Click here to get full coverage on EFG Asset Management North America Corp. Has $2.23 Million Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat

EFG Asset Management North America Corp. Has $2.23 Million Stock Holdings in Immunovant, Inc. $IMVT  MarketBeat

EFG Asset Management North America Corp. Has $2.23 Million Stock Holdings in Immunovant, Inc. $IMVT - MarketBeat

Click here to get full coverage on Insider Sale: Chief Medical Officer of $IMVT Sells 1,160 Shares - Quiver Quantitative

Insider Sale: Chief Medical Officer of $IMVT Sells 1,160 Shares  Quiver Quantitative

Insider Sale: Chief Medical Officer of $IMVT Sells 1,160 Shares - Quiver Quantitative

Click here to get full coverage on Canada Pension Plan Investment Board Has $3.12 Million Position in Immunovant, Inc. $IMVT - MarketBeat

Canada Pension Plan Investment Board Has $3.12 Million Position in Immunovant, Inc. $IMVT  MarketBeat

Canada Pension Plan Investment Board Has $3.12 Million Position in Immunovant, Inc. $IMVT - MarketBeat

Click here to get full coverage on Why This Biotech Just Underwent A Surprise C-Suite Sweep - Investor's Business Daily

Why This Biotech Just Underwent A Surprise C-Suite Sweep  Investor's Business Daily

Why This Biotech Just Underwent A Surprise C-Suite Sweep - Investor's Business Daily

Click here to get full coverage on IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT - Eastern Progress

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT  Eastern Progress

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT - Eastern Progress

Click here to get full coverage on Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) - Seeking Alpha

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT)  Seeking Alpha

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) - Seeking Alpha

Click here to get full coverage on Immunovant Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution - simplywall.st

Immunovant Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution  simplywall.st

Immunovant Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution - simplywall.st

Click here to get full coverage on IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm - FinancialContent

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm  FinancialContent

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm - FinancialContent

Click here to get full coverage on Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance

Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024?  Yahoo Finance

Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance

Click here to get full coverage on Batoclimab data in Graves’ could signal bigger Immunovant win - BioWorld MedTech

Batoclimab data in Graves’ could signal bigger Immunovant win  BioWorld MedTech

Batoclimab data in Graves’ could signal bigger Immunovant win - BioWorld MedTech

Click here to get full coverage on Oppenheimer Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $54 - 富途牛牛

Oppenheimer Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $54  富途牛牛

Oppenheimer Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $54 - 富途牛牛

Click here to get full coverage on Clinical Trial Breakthrough: Immunovant's Batoclimab Shows Remarkable 74% Improvement in MG Patients - Stock Titan

Clinical Trial Breakthrough: Immunovant's Batoclimab Shows Remarkable 74% Improvement in MG Patients  Stock Titan

Clinical Trial Breakthrough: Immunovant's Batoclimab Shows Remarkable 74% Improvement in MG Patients - Stock Titan

Click here to get full coverage on Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another - BioSpace

Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another  BioSpace

Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another - BioSpace

Click here to get full coverage on Stifel lowers Immunovant stock price target to $50 from $61, maintains Buy - Investing.com

Stifel lowers Immunovant stock price target to $50 from $61, maintains Buy  Investing.com

Stifel lowers Immunovant stock price target to $50 from $61, maintains Buy - Investing.com

Click here to get full coverage on Roivant brings rare disease program closer as Immunovant CEO retires - Endpoints News

Roivant brings rare disease program closer as Immunovant CEO retires  Endpoints News

Roivant brings rare disease program closer as Immunovant CEO retires - Endpoints News

Click here to get full coverage on Biotechs Rise After Putting Phase 3 Winner On Back Burner - Investor's Business Daily

Biotechs Rise After Putting Phase 3 Winner On Back Burner  Investor's Business Daily

Biotechs Rise After Putting Phase 3 Winner On Back Burner - Investor's Business Daily

Click here to get full coverage on Immunovant Stockholders Approve Key Governance Decisions - TipRanks

Immunovant Stockholders Approve Key Governance Decisions  TipRanks

Immunovant Stockholders Approve Key Governance Decisions - TipRanks

Click here to get full coverage on A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $30 to $54 - 富途牛牛

A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $30 to $54  富途牛牛

Immunovant Inc (IMVT)

Price Chart

Key Statistics

Technicals

About IMVT

Latest News

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA - GlobeNewswire

Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Immunovant, Inc. $IMVT Shares Bought by Woodline Partners LP - MarketBeat

Advanced Charts

Top Gainers

Top Losers